Abstract

FORMULATION DEVELOPMENT OF NOVEL PLGA NANOPARTICLE FOR CO-DELIVERY OF DOCETAXEL AND PREDNISONE FOR THE TREATMENT OF PROSTATE CANCER

Suparna Ghosh (Ray) and Sayantan Ray*

Abstract

In the current study PLGA [poly (D, L-lactide-co-glycolide)] polymer encapsulated dual drug loaded (Prednisone and Docetaxel) nanoparticle has been reported for treatment of prostate cancer. Two different drugs have been intercalated within polymeric carrier by simple single emulsion solvent evaporation technique. After intercalation of the drug within polymeric matrix system the resultant nanoformulation known as PLGA-prednisone –docetaxel was characterized by using laser light scattering to determine average particle size and size distribution, further dissolution study was carried out in phosphate buffer saline (PBS) at pH 7.4, which exhibited sustained release profile of both the drug prednisone and docetaxel for a prolonged period of 240 h. The in vitro cell cytotoxicity study of PLGA-prednisone-docetaxel nanoparticle was carried out using human prostate cancer cell line, as per standard protocol, that exhibited significant inhibition of the cancer cell proliferation approximately two times more compared to the drug alone prednisone and docetaxel. To the best of our knowledge, this is the first ever report of the use of PLGA polymer encapsulated prednisone and docetaxel dual drug delivery for treatment of prostate cancer.

Keywords: Prednisone; cell viability; in-vitro; sustained release.